FDA in the Shutdown: Drug Center Stays Open (Mostly); Ben Venue Does Not
This article was originally published in RPM Report
Executive Summary
New drug approvals continued during the partial government shutdown, as user fees helped keep most of the FDA review functions running smoothly. The drug center did face some unusual challenges, including responding to a major manufacturing shutdown (by Ben Venue) – and to speculation about a leadership change at the drug center.
You may also be interested in...
FDA In Twilight: Gov’t Shutdown Has Not Slowed Rx Operations Too Visibly Yet
Shutdown puts API shipments on a slow boat, but reviews of existing products can proceed with carry-over funds, even as new applications cannot be filed. CDC has largely halted its influenza program and NIH has ceased enrolling new patients in its clinical center.
FDA’s First “Program” Reviews: Fast Approvals, But Still Some Surprises
The Food & Drug Administration is approving the first products under the new PDUVA V review process. The Program, as it is known, gives FDA an extra two months with an application in exchange for additional meetings for sponsors. It’s designed to help reduce the number of late-cycle “surprises.” There have been a few hiccups, but so far, it appears to be doing just that.
Virtual Advisory Committees: US FDA Clears A Big Test With OxyContin Meeting
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: